Anti-Human Integrin alpha V/CD51 Reference Antibody (Intetumumab, RUO)

Description: Intetumumab (BS10139) is a research-grade recombinant antibody targeting CD51. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: MSK8,VNRA,Vitronectinreceptor,Integrinalpha-V,Vitronectinreceptorsubunitalpha,CD51,ITGAV,VTNR,GPIIIa,Integrinbeta-3,CD61,ITGB3,PlateletmembraneglycoproteinIIIa,GP3A
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: CNTO095,CAS:725735-28-4
Background: Etaracizumab (LM 609) is an αvβ3 integrin IgG1 monoclonal antibody. Etaracizumab inhibits angiogenesis and melanoma tumor growth. Etaracizumab can be used to research anticancer.
Note: For research use only. Not suitable for clinical or therapeutic use.